Author

P. Spiess

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Post-chemotherapy retroperitoneal lymph node dissection following first-line treatment in patients with advanced pure seminoma of the testis.

PURPOSE To report oncological, functional outcomes and surgery-associated complications for post-chemotherapeutic retroperitoneal lymphadenectomy (PC-RPLND) after first-line chemotherapy in patients with pure metastatic seminoma. MATERIAL AND METHODS Retrospective international, multi-institutional study of PC-RPLND...

Axel Heidenreich, S. Daneshmand, P. Spiess et al. · Journal of Urology · 0 citations

Sep 2026

Risk-dependent Benefit of Adjuvant Pembrolizumab in High-risk Clear Cell Renal Cell Carcinoma: A Multi-institutional Study.

BACKGROUND Adjuvant pembrolizumab improves outcomes in high-risk clear cell renal cell carcinoma (ccRCC), but baseline recurrence risk varies substantially. OBJECTIVE To evaluate treatment selection, outcomes, toxicity, and risk-stratified benefit. DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort of consecu...

D. D. Shapiro, D. Roadman, V. Master et al. · European Urology Oncology · 1 citation

Sep 2026

A phase II study assessing the feasibility and clinical efficacy of adaptive immunotherapy combination with VEGFR-TKI in patients with advanced renal cell carcinoma.

Kidney cancer is one of the 10 most common cancers affecting both men and women in the United States, accounting for 4% to 5% of all cancers. Most recent estimates have shown that about 81,610 new cases of kidney cancer will be diagnosed in 2024, with renal cell carcinoma (RCC). The treatment landscape of metastatic or...

Firas Hatoum, Brandon J. Dyer, Jazlyn Heiligh et al. · Future Oncology · 0 citations